Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Randomised, double-blind, double-dummy, vehicle controlled parallel trial comparing a novel mometasone furoate nasal spray vs. Nasonex® nasal spray vs. vehicle nasal spray in patients with allergic rhinitis

    Summary
    EudraCT number
    		 2013-000654-22
    Trial protocol
    		 DE  
    Global end of trial date
    26 Feb 2015

    Results information
    Results version number
    		 v1(current)
    This version publication date
    21 Jul 2016
    First version publication date
    21 Jul 2016
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    13-01/MOM-N
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Dermapharm AG
    Sponsor organisation address
    Lil-Dagover-Ring 7, Gruenwald, Germany, 82031
    Public contact
    Head of Clinical Department, Clinical Department, 0049 08964186-0,
    Scientific contact
    Head of Clinical Department, Clinical Department, 0049 08964186-0,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Feb 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    26 Feb 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    26 Feb 2015
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Evaluation of the efficacy and safety of a new nasal spray with the active ingredient mometasone furoate vs. the originator Nasonex® vs. vehicle in patients with allergic rhinitis.
    Protection of trial subjects
    There were no specific measures necessary.
    Background therapy
    		 There was no background therapy.
    Evidence for comparator
    		 The trial aimed to show non-inferiority with regard to the comparator in order to obtain a generic marketing authorization for the test product.
    Actual start date of recruitment
    20 Aug 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 101
    Worldwide total number of subjects
    101
    EEA total number of subjects
    101
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    93
    From 65 to 84 years
    8
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 all study centers in Germany; first patient first visit: 16. September 2013; last patient last visit: 26. February 2015

    Pre-assignment
    Screening details
    		 Main inclusion criteria: Women or men ≥ 18 years of age; Diagnosis of persistent allergic rhinitis: symptoms present for more than 4 consecutive weeks; the patient is clinically symptomatic with the following baseline symptom scores after 1 week of screening: iTNSS ≥ 6, with nasal congestion score ≥ 2, and rhinorrhea, nasal itching or sneezing ≥ 2

    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Data analyst
    Blinding implementation details
    The devices for administration of test and reference are visually different. Therefore a double-dummy study design was chosen to facilitate double-blind application of the study drugs. Each patient received two devices with stochastical assignment of the active ingredient preparation to one of the devices. He/she had to apply the study medication from both devices in a pre-specified sequence throughout the course of the study.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Mometasone nasal spray
    Arm description
    		 Treatment arm with active ingredient in the test device
    Arm type
    		 Experimental

    Investigational medicinal product name
    Mometasone furoate nasal spray
    Investigational medicinal product code
    R01AD09
    Other name
    Pharmaceutical forms
    Nasal spray, emulsion
    Routes of administration
    Intranasal use
    Dosage and administration details
    One actuation of nasal spray per nostril twice daily was applied (50 µg mometasone furoate per actuation). The resulting total daily dose was 200 µg mometasone furoate.

    Arm title
    		 Nasonex
    Arm description
    		 Treatment arm with active ingredient in the reference device
    Arm type
    		 Active comparator

    Investigational medicinal product name
    Nasonex
    Investigational medicinal product code
    R01AD09
    Other name
    Pharmaceutical forms
    Nasal spray, emulsion
    Routes of administration
    Intranasal use
    Dosage and administration details
    One actuation of nasal spray per nostril twice daily was applied (50 µg mometasone furoate per actuation). The resulting total daily dose was 200 µg,

    Arm title
    		 Placebo
    Arm description
    		 Treatment arm without active ingredient in both devices
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Nasal spray, emulsion
    Routes of administration
    Intranasal use
    Dosage and administration details
    One actuation of nasal spray per nostril, twice daily

    Number of subjects in period 1
    		Mometasone nasal spray Nasonex Placebo
    Started
    43
    36
    22
    Completed
    39
    34
    19
    Not completed
    4
    2
    3
         Adverse event, non-fatal
    1
    2
    1
         Patient's request because of healing
    2
    -
    1
         Protocol deviation
    1
    -
    -
         Lack of efficacy
    -
    -
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment period
    Reporting group description
    		 -

    Reporting group values
    		 Treatment period Total
    Number of subjects
    		 101 101
    Age categorical
    Units: Subjects
        In utero
    		 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0
        Newborns (0-27 days)
    		 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0
        Children (2-11 years)
    		 0 0
        Adolescents (12-17 years)
    		 0 0
        Adults (18-64 years)
    		 93 93
        From 65-84 years
    		 8 8
        85 years and over
    		 0 0
    Gender categorical
    Units: Subjects
        Female
    		 66 66
        Male
    		 35 35
    Subject analysis sets

    Subject analysis set title
    Safety data set
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    comprises all patients who had administered the study medication at least once and provide any follow-up data

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    		 Intention-to-treat
    Subject analysis set description
    includes all patients of the safety data set who comply with the study diagnosis (according to the associated inclusion criteria) and provide the baseline value and at least one post baseline value of the TNSS (either iTNSS or rTNSS)

    Subject analysis sets values
    		 Safety data set Full Analysis Set
    Number of subjects
    101
    101
    Age categorical
    Units: Subjects
        In utero
    0
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
    0
        Newborns (0-27 days)
    0
    0
        Infants and toddlers (28 days-23 months)
    0
    0
        Children (2-11 years)
    0
    0
        Adolescents (12-17 years)
    0
    0
        Adults (18-64 years)
    93
    93
        From 65-84 years
    8
    8
        85 years and over
    0
    0
    Age continuous
    Units:
        
    ( )
    ( )
    Gender categorical
    Units: Subjects
        Female
    66
    66
        Male
    35
    35

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Mometasone nasal spray
    Reporting group description
    		 Treatment arm with active ingredient in the test device

    Reporting group title
    Nasonex
    Reporting group description
    		 Treatment arm with active ingredient in the reference device

    Reporting group title
    Placebo
    Reporting group description
    		 Treatment arm without active ingredient in both devices

    Subject analysis set title
    Safety data set
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    comprises all patients who had administered the study medication at least once and provide any follow-up data

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    		 Intention-to-treat
    Subject analysis set description
    includes all patients of the safety data set who comply with the study diagnosis (according to the associated inclusion criteria) and provide the baseline value and at least one post baseline value of the TNSS (either iTNSS or rTNSS)

    Primary: Treatment effect

    		 Close Top of page
    End point title
    		 Treatment effect [1]
    End point description
    change of DrTNSS between start and end of treatment; calculated as the mean of the morning assessments (AMrTNSS) and the evening assessments (PMrTNSS) of the Reflective Total Nasal Symptom Score (rTNSS) in the patient diaries
    End point type
    Primary
    End point timeframe
    Between Start and End of Treatment.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Due to the substantial reduction in sample size there was not enough power to investigate the primary objectives of the study (statistical equivalence of the active treatments and superiority of both preparations over placebo) in a reliable way. The primary efficacy parameter is therefore only displayed in a descriptive way.
    End point values
    		 Mometasone nasal spray Nasonex Placebo Full Analysis Set
    Number of subjects analysed
    43
    36
    22
    101
    Units: score units
        median (full range (min-max))
    -6.5 (-11.5 to 3.5)
    -5.8 (-10.5 to 1)
    -6.5 (-9 to -1)
    -6.5 (-11.5 to 3.5)
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Inclusion visit (= start of screening) to End of treatment (Main visit)
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    18.0
    Reporting groups
    Reporting group title
    Mometasone nasal spray
    Reporting group description
    		 Treatment arm with active ingredient preparation in test device

    Reporting group title
    Nasonex
    Reporting group description
    		 Treatment arm with active ingredient in the reference device

    Reporting group title
    Placebo
    Reporting group description
    		 Treatment arm without active ingredient in both devices

    Serious adverse events
    		 Mometasone nasal spray Nasonex Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Frequency threshold for reporting non-serious adverse events: 0.05%
    Non-serious adverse events
    		 Mometasone nasal spray Nasonex Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    13 / 43 (30.23%)
    17 / 36 (47.22%)
    11 / 22 (50.00%)
    General disorders and administration site conditions
    Mucosal dryness
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Allergic pharyngitis
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Asthma
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Cough
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Dysphonia
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Epistaxis
         subjects affected / exposed
    1 / 43 (2.33%)
    3 / 36 (8.33%)
    1 / 22 (4.55%)
         occurrences all number
    1
    5
    1
    Nasal discomfort
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Nasal dryness
         subjects affected / exposed
    1 / 43 (2.33%)
    1 / 36 (2.78%)
    1 / 22 (4.55%)
         occurrences all number
    1
    1
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Rhinitis atrophic
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Sneezing
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Throat irritation
         subjects affected / exposed
    1 / 43 (2.33%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    1
    1
    0
    Investigations
    Blood cortisol increased
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Platelet count increased
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Injury, poisoning and procedural complications
    Post-traumatic pain
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Stab wound
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Headache
         subjects affected / exposed
    1 / 43 (2.33%)
    2 / 36 (5.56%)
    4 / 22 (18.18%)
         occurrences all number
    1
    2
    5
    Blood and lymphatic system disorders
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Eye disorders
    Eczema eyelids
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Eye allergy
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Skin and subcutaneous tissue disorders
    Dermatitis allergic
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Eczema
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Renal and urinary disorders
    Cystitis noninfective
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Back pain
         subjects affected / exposed
    1 / 43 (2.33%)
    0 / 36 (0.00%)
    0 / 22 (0.00%)
         occurrences all number
    1
    0
    0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    1 / 22 (4.55%)
         occurrences all number
    0
    1
    1
    Infectious mononucleosis
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    0
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    3 / 43 (6.98%)
    4 / 36 (11.11%)
    1 / 22 (4.55%)
         occurrences all number
    3
    4
    1
    Oral herpes
         subjects affected / exposed
    1 / 43 (2.33%)
    1 / 36 (2.78%)
    0 / 22 (0.00%)
         occurrences all number
    1
    1
    0
    Rhinitis
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 43 (0.00%)
    1 / 36 (2.78%)
    1 / 22 (4.55%)
         occurrences all number
    0
    1
    1
    Metabolism and nutrition disorders
    Zinc deficiency
         subjects affected / exposed
    0 / 43 (0.00%)
    0 / 36 (0.00%)
    1 / 22 (4.55%)
         occurrences all number
    0
    0
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    26 Feb 2015
    The trial was prematurely ended due to a low recruitment rate. There were no safety concerns.
    -

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 06:25:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA